

Contents lists available at [ScienceDirect](https://www.sciencedirect.com)

Current Research in Pharmacology and Drug Discovery

journal homepage: www.journals.elsevier.com/current-research-in-pharmacology-and-drug-discovery

Indole: A promising scaffold for the discovery and development of potential anti-tubercular agents

Nilesh Gajanan Bajad^a, Sudhir Kumar Singh^b, Sushil Kumar Singh^a, Tryambak Deo Singh^c, Meenakshi Singh^{c,*}

^a Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, 221005, India

^b Department of Microbiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, India

^c Department of Medicinal Chemistry, Faculty of Ayurveda, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, India

ARTICLE INFO

Keywords:

Indole
Tuberculosis
Computer-aided drug design
Clinical trials
In vitro
In silico
Synthesis
Indole alkaloids
Drug discovery
Drug development

ABSTRACT

Indole-containing small molecules have been reported to have diverse pharmacological activities. The aromatic heterocyclic scaffold, which resembles various protein structures, has received attention from organic and medicinal chemists. Exploration of indole derivatives in drug discovery has rapidly yielded a vast array of biologically active compounds with broad therapeutic potential. Nature is the major source of indole scaffolds, but various classical and advanced synthesis methods for indoles have also been reported. One-pot synthesis is widely considered an efficient approach in synthetic organic chemistry and has been used to synthesize some indole compounds. The rapid emergence of drug-resistant tuberculosis is a major challenge to be addressed. Identifying novel targets and drug candidates for tuberculosis is therefore crucial. Researchers have extensively explored indole derivatives as potential anti-tubercular agents or drugs. Indole scaffolds containing the novel non-covalent (decaprenylphosphoryl- β -D-ribose^{2'}-epimerase) DprE1 inhibitor 1,4-azaindole is currently in clinical trials to treat *Mycobacterium tuberculosis*. In addition, DG167 indazole sulfonamide with potent anti-tubercular activity is undergoing early-stage development in preclinical studies. Indole bearing cationic amphiphiles with high chemical diversity have been reported to depolarize and disrupt the mycobacterial membrane. Some indole-based compounds have potential inhibitory activities against distinct anti-tubercular targets, including the inhibition of cell wall synthesis, replication, transcription, and translation, as summarized in the graphical abstract. The success of computer-aided drug design in the fields of cancer and anti-viral drugs has accelerated *in silico* studies in antibacterial drug development. This review describes the sources of indole scaffolds, the potential for novel indole derivatives to serve as anti-tubercular agents, *in silico* findings, and proposed actions to facilitate the design of novel compounds with anti-tubercular activity.

1. Introduction

Tuberculosis (TB), an infectious disease caused by the bacillus *Mycobacterium tuberculosis* (*Mtb*), remains a leading cause of morbidity and mortality worldwide (Kontsevaya et al., 2021). In the year 2017, TB was announced as matter of high priority by the World Health Organization (Khawbung et al., 2021). Streptomycin was the first drug discovered to treat TB, and the subsequent entry of thiacetazone and para-aminosalicylic acid into the market improved the cure rate of the disease. The development of resistance to streptomycin resulted in the

discovery of new anti-tubercular drugs such as isoniazid (INH), pyrazinamide, cycloserine, ethionamide, rifampicin, and ethambutol (Chetty et al., 2017). The World Health Organization recommends directly observed treatment, short-course anti-TB therapy including INH, rifampicin, pyrazinamide, and ethambutol as first-line drugs. The *Mycobacterium* genome, after undergoing mutation and several other structural changes, can evade the drugs commonly used to treat the infection. This drug resistance can also decrease drug accumulation in the bacterium or inactivation due to mutation. A decrease in the drug's binding affinity to target genes has also been observed. The control

Abbreviations: DprE1, decaprenylphosphoryl- β -D-ribose^{2'}-epimerase; KasA, β -ketoacyl ACP synthase I; MmpL3, mycobacterial membrane protein large 3; CM, chorismate mutase; DHFR, Dihydrofolate reductase; SBDD, Structure-based drug design.

* Corresponding author.

E-mail address: meenakshisingh@bhu.ac.in (M. Singh).

<https://doi.org/10.1016/j.crphar.2022.100119>

Received 27 December 2021; Received in revised form 13 April 2022; Accepted 5 July 2022

2590-2571/© 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

measures and medications for the disease have been complicated by the outbreak of resistance (Rivers and Mancera, 2008).

The emergence of drug-resistant bacteria is the primary concern regarding the ineffectiveness of first-line drugs. Several new drug candidates with novel mechanisms of action are currently under development (Rivers and Mancera, 2008). Thus, new drugs with novel and existing mechanisms of action with minimal or no drug resistance are currently needed. Indoles (C_8H_7N) are aromatic heterocyclic structures consisting of a benzene ring fused to a five-membered nitrogen-containing pyrrole ring. The therapeutic potential of indole-containing small molecules has been reported, on the basis of their various pharmacological activities (Kumari and Singh, 2019). Many drug molecules containing an indole ring have been marketed for the treatment of various disease conditions. These drugs include the anticancer drugs vincristine, vinblastine, vinorelbine, vindesine, mitraphylline, and apaziquone (marketed as an anti-microbial agent), and also anti-hypertensive drugs, such as vincamine, reserpine, and perindopril. Some anti-depressant drugs have also been marketed, such as binedaline, trandolapril, amedalin, pindolol, siramesine, and indalpine (Fig. 1) (Biswal et al., 2012). Several mechanisms that inhibit mycobacterial strains have been explored, such as inhibition of cell wall synthesis, mycolic acid synthesis, protein synthesis, RNA synthesis, ATP synthase, DNA topoisomerase, and DNA gyrase (Chetty et al., 2017; Rivers and Mancera, 2008; Mitchison and Davies, 2008). Mechanistic and computational studies of novel indoles derivatives against mycobacteria have revealed the modes of action of various compounds. Here, we summarize the sources of indole scaffolds and the proposed modes of action of novel indole-based compounds (Tables 1–7), which may serve as anti-tubercular drugs against various targets. We also highlight the potential findings from an *in silico* approach to discovering and developing anti-tubercular agents.

2. Sources of indole scaffolds

Indole moieties are found in various bioactive molecules of natural and synthetic origin. Nature is a major source of small molecules with a wide range of biological activities and structural complexities that enable the design of novel therapeutic agents (de Sa Alves et al., 2009; Bajad et al., 2021a). Indole alkaloids have been described to have high therapeutic importance. The alkaloids are widely distributed in plant families such as Apocynaceae, Rubiaceae, Loganiaceae, and Nyssaceae. The principal genera containing alkaloids include *Geissospermum*, *Alstonia*, *Rauvolfia*, *Aspidosperma*, *Tabernaemontana*, *Psychotria*, *Kopsia*, *Hexalobus*, *Gelsemium*, and *Vinca* (Rosales et al., 2020). The important pharmacologically active classes of indole




Fig. 1. Indole scaffolds in several marketed drugs.

alkaloids include the antitumor drugs vinblastine and vincristine from *Catharanthus roseus*, and the antihypertensive drug reserpine from *Rauvolfia serpentina* (Hamid et al., 2017). Several indole alkaloids of marine origin have been isolated from sponges, seaweeds, ascidians, and mollusks (Kochanowska-Karamyan and Hamann, 2010). The marine-derived indole alkaloids are promising molecules with various biological activities, including anti-inflammatory, anti-parasitic, cytotoxic, antiviral, serotonin modulating, and antagonistic functions (Dey et al., 2020). The structural similarity of indole alkaloids to endogenous neurotransmitters endows the molecules with neurological activity and affinity toward serotonin receptors (Kochanowska-Karamyan and Hamann, 2010). In 1866, Adolf von Baeyer first synthesized indole from oxindole by using zinc dust (Baeyer and Knop, 1866). Various classical and advanced synthesis methods for indoles have since been reported, including Fischer indole synthesis, the classical and widely used method for synthesizing indole and its derivatives (Gassman et al., 1974; Bhakhar et al., 2022). Other modern versions of classical synthetic methods include Nenitzescu synthesis, Reiser synthesis, Ullmann reaction, Leimgruber-Batcho synthesis, Madelung synthesis, the Bartoli reaction, and the Cadogan-Sundberg reaction (Bugenko et al., 2019; Humphrey and Kuethe, 2006). The transition metal-catalyzed cyclization reactions of unsaturated substrates have become a powerful tool for constructing indole rings (Neto and Zeni, 2020).

3. Indole-based anti-tubercular compounds

3.1. Cell wall inhibitors





The architecture of the mycobacterial cell wall is uniquely composed of a double-membrane cell envelope rich in lipids and carbohydrates, which forms a permeability barrier that blocks the passage of several drug molecules (Hett and Rubin, 2008). The first challenge of any anti-mycobacterial drug is to penetrate this barrier before reaching its target and exerting its potential action. Cell wall biosynthesis inhibition has been demonstrated to be a promising and validated drug target of many discovered anti-mycobacterial drugs (Bugg et al., 2011). The cell envelope comprises three major domains: the characteristic long-chain mycolic acids, highly branched arabinogalactan polysaccharide, and crossed-linked peptidoglycan network (Jankute et al., 2015). The involvement of multiple enzymes in the complex cell wall architecture provides several potential targets for developing new drugs against drug-resistant forms of *Mtb* (Chen et al., 2018). Targeting of different proteins, e.g., alanine racemase, L, D-transpeptidase (LdtMt2), L, D-transpeptidase (LdtMt1), galactofuranosyl transferase, Pks13, Acyl-MP ligase, FabH, InhA (E), MabA, and DprE1, can inhibit cell wall synthesis (Chetty et al., 2017). Several indole scaffold containing agents have been reported to inhibit cell wall biosynthesis by targeting specific enzymes or proteins. Mycolic acids are the most essential primary constituent of the mycobacterial cell wall, contributing to its integrity and permeability. Several key enzymes that are involved in the biosynthesis of mycolic acids, including fatty acid synthesis, and are excellent drug targets include KaS, MabA, KasB, InhA, and HadABC; mycolic acid modifying enzymes; aNAT, SAM-dependent methyltransferases; fatty acid activating and condensing enzymes; and Pks13, FadD32, Acc, transporters (MmpL3), and transferases (antigen 85A-C) (Jeffrey North et al., 2014). The incidence of drug resistance increases with the currently clinically available mycolic acid inhibitors, including isoniazid, ethionamide, and nitroimidazoles. Therefore, the development of new drugs, particularly those inhibiting mycolic acids, may be a promising approach. Some potential indole-containing mycolic acid inhibitors, including their synthesis and biological evaluation against different targets, have been reported. The iso-indole-based compound 2-hydroxy-4-(4-nitro-1,3-dioxoisindolin-2-yl) benzoic acid (IDDB40) (Kontsevaya et al., 2021) exhibits strong activity against all strains of *Mtb* with mycolic acid inhibition. The 2-hydroxy-4-(4-nitro-1,3-dioxoisindolin-2-yl)

Table 1
Indole-based cell wall inhibitors.

Sr. No	Compound	Structure	% Inhibition/ IC50	Ref.
1.	2-Hydroxy-4-(4-nitro-1,3-dioxisoindolin-2-yl) benzoic acid (IDDB40)		0.39 µg/ml	(Islam et al., 2021)
2.	GEQ analog, 3-(9H-fluoren-9-yl)-1-(1H-indol-5-ylcarbonyl)-2,5-pyrrolidinedione		39.4 µM	(Matviuk et al., 2013)
3.	Spiro[indole-thiazolidine] derivatives		12.5 µg/ml	(Borad et al., 2018)
4.	3-(3-(5-Chloro-2-phenyl-1H-indol-3-yl)-1-isonicotinoyl-1H-pyrazol-5-yl)-2H-chromen-2-one		12.5 µg/ml	(Rathod et al., 2017)
5.	Indole-3-thiosemicarbazone (H1L)		1.6 µg/ml	(Khan et al., 2018)
6.	Indole-based 1,3,4-oxadiazole derivatives		28.72 µg/ml	(Desai et al., 2016)

(continued on next page)

Table 1 (continued)

Sr. No	Compound	Structure	% Inhibition/ IC50	Ref.
7.	N-(2-hydroxyethyl)-1-((6-methoxy-5-methylpyrimidin-4-yl) methyl)-6-methyl-1H pyrrolo[3,2-b] pyridine-3-carboxamide		10 nM	(Chatterji et al., 2014)
8.	N-(4-(4-(bis(5-bromo-1H-indol-3-yl)methyl)-1H-1,2,3-triazol-1-yl) phenyl)acetamide		1 µg/mL	Danne et al. (2018)
9.	DG167, indazole sulfonamide		0.39 µM	(Inoyama et al., 2020)
10.	Indole chalcones		210 µM	(Ramesh et al., 2020)



benzoic acid (IDDB40) (Kontsevaya et al., 2021) compound has been found to have isoniazid activity in a preliminary study of mycolic acid inhibition and may be a potential anti-TB agent (Islam et al., 2021).

3.1.1. Enoyl acyl carrier protein reductase (InhA) inhibitors

The two main elongation systems that control mycolic acid biosynthesis are fatty acid synthase type I (FAS-I) and fatty acid synthase type II (FAS-II). Because eukaryotic cells use FAS-1 enzymes, inhibition of FAS-II enzymes is a viable target in drug development. The enoyl acyl carrier protein reductase (InhA or ENR) of the FAS-II system is involved in the catalysis of NADH-dependent reduction of the double bond at the second position of the growing fatty acid chain associated with ACP (Rožman et al., 2017). The *Mtb* ENR, commonly known as InhA or Fab I, has been shown to be a potential target for developing anti-tubercular drugs (Kuo et al., 2003). The succinimide and indole scaffold containing the GEQ analog 3-(9H-fluoren-9-yl)-1-(1H-indol-5-ylcarbonyl)-2,5-pyrrolidinedione (Khawbung et al., 2021) potentially inhibits InhA from *Mtb* with an IC50 of 39.4 µM. The 5-indole carbonyl derivatives have been found to moderately inhibit InhA (Matviiuk et al., 2013). Several *in silico* findings with respect to InhA inhibition have been reported for indole derivatives. A series of novel spiro[indole-thiazolidines] (Chetty et al., 2017) derivatives have been synthesized from 5-substituted isatin derivatives and thioglycolic acid, with ZrSiO₂ as an efficient catalyst under microwave

irradiation, and have been evaluated against the *Mtb* H37Rv strain. The *in silico* analysis of synthesized compounds with the target long-chain enoyl acyl carrier protein reductase (InhA) has identified several promising compounds (Borad et al., 2018). Various indole, coumarinyl, pyridinyl, and INH derivatives (Rivers and Mancera, 2008) have been synthesized and evaluated against the *Mtb* H37Rv strain. The computational data from molecular docking studies of all compounds against the InhA enzyme, as well as data from *in vitro* assays, have been found to replicate the experimental anti-TB activity (Rathod et al., 2017). The synthesized complexes of indole-3-thiosemicarbazone (H1L) (Kumari and Singh, 2019), 5-methoxy indole-3-thiosemicarbazone (H3L), indole-N1-methyl-3-thiosemicarbazone (HIntsc-N1-Me, H2 L), and 5-methoxy indole-N1-methyl-3-thiosemicarbazone (H4L) with copper (I) and silver (I) have been tested for their antimicrobial activity. The compounds have also been evaluated for their binding affinity by docking against ENR, and the active indole-3-thiosemicarbazone and its complexes have shown favorable binding affinity toward the target (Khan et al., 2018). The evaluation of a series of indole- and pyridine-based 1,3,4-oxadiazole derivatives (Biswal et al., 2012) has been performed to determine the *in vitro* anti-tubercular activity against *Mtb* H37Ra and *Mycobacterium bovis* BCG, in both inactive and dormant states, and some of the compounds have shown favorable anti-TB activity. Additional *in silico* studies against InhA have suggested that the

Table 2
Indole-based cell membrane depolarizers.

Sr. No	Compound	Structure	% Inhibition/ IC50	Ref.
11.	n-Octyl side chain containing 4-fluoro-3-[(azepan-1-yl)methyl] indole		2 μ M	(Yang et al., 2017)
12.	Indolylpropyl-triphenylphosphonium		3 μ M	(Li et al., 2017)

compounds have excellent potential for further optimization and development (Desai et al., 2016).

3.1.2. Decaprenylphosphoryl- β -D-ribose 2'-epimerase (DprE1) inhibitors

The target DprE1 is a crucial enzyme in cell wall synthesis in *Mycobacterium*. DprE1 is a flavoprotein that plays a crucial role in the synthesis of arabinogalactan and lipoarabinomannan, the critical mycobacterium cell-wall polysaccharides (Chikhale et al., 2018). The 1,4-azaindoles are potential drug candidates for the management of TB through the non-covalent inhibition of DprE1. One molecule in the 1,4-azaindole class (TBA 7371) (Mitchison and Davies, 2008) is currently in clinical trials for the treatment of *Mtb* (NCT04176250). These compounds inhibit DprE1 with an IC50 value of 10 nM and have also been shown to be active against *Mtb* with a minimal inhibitory concentration (MIC) of 0.78–3.12 μ M (Robertson et al., 2021; Shirude et al., 2013) (Chatterji et al., 2014). A triazole-diindolylmethane conjugate (de Sa Alves et al., 2009) compound has been found to have substantial *in vitro* activity against *Mtb* H37Ra. The favorable binding of compounds in the active site of the DprE1 enzyme has also been demonstrated with molecular docking studies (Danne et al., 2018).

3.1.3. β -ketoacyl ACP synthase I (KasA) inhibitors

KasA is an essential member of three β -ketoacyl synthases encoded in the genome of *Mtb*. This enzyme actively participates in the catalysis of 2-carbon elongation of growing fatty acyl chains in the FAS-II pathway, which is essential in the biosynthesis of mycolic acids (Kumar et al., 2018) DG167, an indazole sulfonamide (Bajad et al., 2021a) inhibitor of KasA, is undergoing early-stage development in preclinical studies and has been reported to have an MIC of 0.39 μ M against the wild-type H37Rv strain and to lack cross-resistance with front line TB agents. Another preclinical candidate, JSF-3285, has been developed to optimize DG167 (Inoyama et al., 2020; Kumar et al., 2021). *Mtb* indole chalcones (Rosales et al., 2020) have been demonstrated to inhibit the H37Rv strain of *Mtb* with an MIC of 210 μ M and to show favorable *in silico* binding affinity toward KasA (Ramesh et al., 2020).

3.2. Selective cell membrane depolarization with the indole bearing motif

The selective targeting of the bacterial cell membrane is considered a novel targeting method for anti-tubercular drugs. Targeting of the intact cell membrane, which is crucial for the survival of bacteria, has been found to disrupt a multitude of embedded targets and to have lethal pleiotropic consequences (Chen et al., 2018). Furthermore, those antibacterial agents selectively inhibit the function of the mycobacterial membrane, thus delaying the emergence of resistance, decreasing relapse, and shortening the treatment period for TB. The selective cell membrane permeabilization and depolarization is based on the incorporation of a cationic amphiphilic motif in the form of a lipophilic n-octyl side chain and positively charged azepanyl in the 4-fluoro and 6-methoxyindoles (Hamid et al., 2017), which have shown potent anti-mycobacterial activity, solubility, and metabolic stability (Yang et al., 2017). Furthermore, other indole bearing lipophilic moieties and extensively charge-delocalized triphenylphosphonium cations have been used as a membrane-targeting motif. The indolylalkyl-triphenylphosphonium (Kochanowska-Karamyan and Hamann, 2010) analogs have shown potent antibacterial activity through sustained depolarization and disruption of mycobacterial membranes (Li et al., 2017).

3.3. Mycolic acid transporter MmpL3 inhibitors

The mycobacterial membrane protein large 3 (MmpL3) is involved primarily in the transport of mycolic acids in trehalose-monomycolates, precursors of trehalose-dimycolates, and mycolates, which are essential components of the mycobacterial outer membrane (Bolla, 2020). The inhibition of MmpL3 weakens the mycobacterial cell wall and leads to cell death, thus serving as a new potential target for developing novel anti-tubercular drugs (Rayasam, 2014). MmpL3 inhibitors are identified primarily through whole cell-based screening and mutant generation coupled with whole-genome sequencing (Rayasam, 2014). Franz et al. have designed, synthesized, and evaluated indole-2-carboxamides (Dey et al., 2020) for their anti-mycobacterial activity. The indole-2-carboxamides have been tested against several fast- and

Table 3
Indole-based MmpL3 inhibitors.

Sr. No.	Compound	Structure	% Inhibition/ IC50	Ref.
13.	Indole-2-carboxamides		0.2 µg/ml	(Franz et al., 2017)
14.	N-cyclooctyl-6-trifluoromethylindol-2-ylmethylamine		0.13 µM	(Tan et al., 2020)
15.	N-(1-(adamantan-1-yl) ethyl)-4,6-dichloro-1H-indole-2-carboxamide		0.32 µM	(Alsayed et al., 2021)
16.	Adamantanol analogs		NA	(Alsayed et al., 2021)
17.	NITD-349, N-(4,4-dimethylcyclohexyl)-4,6-difluoro-1H-indole-2-carboxamide		NA	(Yang et al., 2020)
18.	Indolamide		>64 µg/mL	(Lun et al., 2013)






slow-growing *Mycobacterium* species, including *M. massiliense*, *M. abscessus*, *M. boletii*, *Mtb*, *M. chelonae*, *M. avium*, *M. xenopi*, and *M. smegmatis*. The compounds have been found to inhibit MmpL3 and to have potent pan-activity against mycobacterial species (Franz et al., 2017). Amide-amine replacement in indole-2-carboxamides yields the potent mycobactericidal compound N-cyclooctyl-6-trifluoromethylindol-2-ylmethylamine (Baeyer and Knop, 1866), which has favorable water solubility. The activity is observed after the replacement of carboxamide, but not in the absence of the indole moiety (Tan et al., 2020). Indoleamide analogs have been reported to be MmpL3 inhibitors with anti-tubercular activity. The most potent adamantanol analogs (Gassman et al., 1974; Bhakhar et al., 2022) are highly selective toward drug-sensitive and drug resistant *Mycobacterium* strains and show no cytotoxicity (Alsayed et al., 2021). The crystal structure of MmpL3 complexed with the inhibitors NITD-349 (N-(4,4-dimethylcyclohexyl)-4,6-difluoro-1H-indole-2-carboxamide) (Buganenko et al., 2019), comprising an indole-2-carboxamide, has been studied. NITD-349 binds deep in the central channel of the transmembrane domain and causes conformational changes to the protein. The indole nitrogen of NITD-349 mainly interacts with Asp645, and targets the

proton relay pathway, thereby blocking the activity of MmpL3 (Yang et al., 2020). The targeting of MmpL3 with indoleamides (Humphrey and Kuethe, 2006) has shown potent activity against both drug-susceptible and drug-resistant strains of *Mtb*. The in vivo evaluation of indolamide derivatives has also shown dose-dependent anti-mycobacterial activity after oral administration to mice infected with *Mtb* (Lun et al., 2013).

3.4. Chorismate mutase (CM) inhibitors

The *Mtb* chorismate mutase (*Mtb*CM) catalyzes the conversion of chorismate to prephenate in the shikimate biosynthetic pathway in the synthesis of the essential amino acids phenylalanine and tyrosine. The secretory form, *Mtb*CM, encoded by *Rv1885c*, is believed to actively participate in the pathogenesis of TB. Therefore, the inhibition of CM may directly hinder the supply of nutrients to the organism (Khanapur et al., 2017). A series of isatin-indole (Neto and Zeni, 2020) derivatives synthesized through the one-pot coupling method have been reported to have potential CM inhibitory activity at nanomolar concentrations. Strong interaction has also been observed through *in silico* docking

Table 4
Indole-based chorismate mutase inhibitors.

Sr. No.	Compound	Structure	% Inhibition/ IC50	Ref.
19.	Isatin-indole		74.20% at 30 μ M	(Reddy et al., 2020)
20.	Indole containing o-(RSO ₂) C ₆ H ₄ group		17.02 mM	(Nakhi et al., 2011)
21.	3-((5-Chloro-1-tosyl-1H-indol-2-yl)methyl)benzo[d][1,2,3]triazin-4(3H)-one		78% at 30 μ M	(Reddy et al., 2019)
22.	7-Sulfonyl indole		45% at 30 μ M	(Prasad et al., 2012)
23.	2-Chloro-3-(5,6-difluoro-1H-indol-3-yl)quinoxaline		19.74 μ M	(Kumar et al., 2012)

studies with CM (Reddy et al., 2020). A novel indole containing an o-(RSO₂) C₆H₄ group at C-2 (Hett and Rubin, 2008), synthesized via in situ desilylation-Sonogashira strategies, has been evaluated for *in vitro* *Mtb* H37Rv CM inhibition activity. One compound has shown potent and dose-dependent CM inhibition with an IC₅₀ value of 17.02 μ M (Nakhi et al., 2011). The substantial *in vitro* inhibition of CM at 30 μ M and the potential *in silico* inhibitory activity of 3-indolylmethyl substituted pyrazolotriazinone derivatives (Bugg et al., 2011) have been demonstrated. These compounds were synthesized in a single pot through the Pd/Cu-catalyzed coupling-cyclization approach (Reddy et al., 2019). The

potential CM inhibitory activity of 7-sulfonyl indoles (Jankute et al., 2015) synthesized via AlCl₃ has been found to mediate unexpected regioselective migration of the sulfonyl group (Prasad et al., 2012). Promising CM inhibiting agents have been developed by combining the structural features of indole and the quinoxaline moiety in a single molecule, 2-chloro-3-(5,6-difluoro-1H-indol-3-yl)quinoxaline (Chen et al., 2018), through one pot synthesis of AlCl₃ induced (hetero)arylation of 2,3-dichloroquinoxaline (Kumar et al., 2012).

Table 5
Indole-based compounds targeting DNA replication machinery.


Sr. No.	Compound	Structure	% Inhibition/ IC50	Ref.
24.	3-((1-Oxoindolin-2-ylidene)methyl)phenyl benzoate		NA	(Kumar et al., 2012)
25.	2-(1H-indol-3-yl) ethylthiourea		72.6 ± 1.2 µg/mL	(Sanna et al., 2018)
26.	3-(1-Benzyl-5-chloro-2-(ethoxycarbonyl)-4-(trifluoromethyl)-1H-indol-3-yl) propanoic acid		86.6 µM	(Singh et al., 2020)
27.	Indole-3-acetic acid-based inhibitor		3.9 µM	(Dewangan et al., 2021)
28.	Tetracyclic indole derivatives		NA	(Yadav et al., 2015)
29.	4-((3-Acetyl-1-benzyl-2-methyl-1H-indol-5-yl) oxy) butanoic acid		150 µM	(Sharma et al., 2018)
30.	1-(1-Benzyl-5-((1-(4-bromophenyl)-1H-1,2,3-triazol-4-yl) methoxy)-2-methyl-1H-indol-3-yl) ethanone		6.79 µM	(Sharma et al., 2019)

Table 6
Miscellaneous indole-based compounds.

Sr. No.	Compound	Structure	% Inhibition/IC50	Ref.
31.	(E)-1-(furan-3-yl)-3-(1H-indol-3-yl) prop-2-en-1-one		87.67%	(Ramesh et al., 2020)
32.	2-(Indol-3-yl)-2-oxo-acetamide		0.9 µg/mL	(Mashayekhi et al., 2021)
33.	3-(1H-indol-3-yl) propanoic acid		68 µM	(Negatu et al., 2018)
34.	Hybrid hydrazides and hydrazide-hydrazones indoles		0.2 µg/mL	(Velezheva et al., 2016)
35.	Indole-benzimidazole-based 1,2,3-triazole hybrids		3.125–6.25 µg/mL	(Ashok et al., 2018)
36.	Indole-based thiosemicarbazones		1.9 µg/mL	(Mashayekhi et al., 2021)

(continued on next page)

Table 6 (continued)

Sr. No.	Compound	Structure	% Inhibition/IC50	Ref.
37.	Indole diketo acids		0.02 μM	(Libardo et al., 2018)

3.5. Targeting DNA replication machinery

The large multi-protein replisome synthesizes leading and lagging strands in bacterial DNA replication. Replisome proteins catalyze several events such as DNA unwinding, RNA primer synthesis, clamp loading, and DNA synthesis (Ditse et al., 2017). The main components of the DNA replication machinery include the DnaA replication initiator, PriA helicase loader, DnaB helicase, DnaG primase, SSB, clamp loader subunits (τ/γ , δ , and δ'), DNA polymerases I and III, DnaN β -clamp, DNA ligase I, and type I and II topoisomerases.

3.5.1. DNA gyrase inhibitors

DNA gyrase is the only clinically validated target of the fluoroquinolones, which inhibit replication and are used to treat multi-drug resistant TB (Reiche et al., 2017). Efforts to design novel DNA gyrase inhibitors are accelerating because of resistance to fluoroquinolones. The pharmacophore model of GyrB has also been used to screen an in-house database. Docking analysis, MM-GBSA, and MD simulations of selective GyrB inhibitors have been performed to validate the selectivity and potency of the molecules toward the GyrB domain and have also been evaluated for their anti-potential activity (Jeffrey North et al., 2014) (Kashyap et al., 2018; Dighe and Collet, 2020). A series of 2-(1H-indol-3-yl) ethylthiourea (Islam et al., 2021) derivatives have been synthesized and evaluated for their antimicrobial activity against Gram-positive cocci, Gram-negative rods, and fungi. One of the compounds, 1-(2-(1H-indol-3-yl)ethyl)-3-(3,4-dichlorophenyl)thiourea, inhibits *S. aureus* topoisomerase IV decatenation activity and *S. aureus* DNA gyrase supercoiling activity (Sanna et al., 2018). A series of potent inhibitors (Rožman et al., 2017) have been developed to target the two enzymes i.e., DnaG primase and DNA gyrase, involved in DNA replication of *Mtb*. Two of the obtained novel selective inhibitors exhibited bacteriostatic activity against *Mycobacterium smegmatis*, a fast-growing non-pathogenic model species of mycobacteria. Impairment of biofilm development has also been observed, thus indicating the therapeutic potential of the molecules against infections caused by planktonic and sessile forms of *Mycobacterium* species (Dewangan et al., 2021). The cell-penetrating peptide conjugates of indole-3-acetic acid-based DNA primase/gyrase 2 inhibitors (Kuo et al., 2003) have been found to be potent anti-tubercular agents. The synthetic conjugates have been evaluated on *M. smegmatis* (a non-pathogenic mycobacteria), and the MIC has been determined. Unexpectedly, the conjugates have been found to be more potent than the free inhibitors (Dewangan et al., 2021; Singh et al., 2020). The tetracyclic indole derivatives (Matviuk et al., 2013) target the bacterial DNA ligases and distinguish them from human DNA ligases. The compounds bind the cofactor binding site and compete with the cofactor, according to *in silico* docking and enzyme inhibition assays (Yadav et al., 2015).

3.5.2. Dihydrofolate reductase (DHFR) inhibitors

DHFR is a key enzyme involved in producing tetrahydrofolate, which is essential for bacterial survival. DHFR is required for the biosynthesis of purine and pyrimidine nucleic acids, which have a major role in cell reproduction (Kleinhans et al., 2010). The selective and potent inhibition of *Mtb*-DHFR by 4-((3-acetyl-1-benzyl-2-methyl-1H-indol-5-yl) oxy) butanoic acid (Borad et al., 2018) has been demonstrated in a structural

comparison of *Mtb*-DHFR and human DHFRs (Sharma et al., 2018). The bioisosteric replacement of these compounds has resulted in new series of 1-(1-benzyl-2-methyl-5-((1-phenyl-1H-1,2,3-triazol-4-yl)methoxy)-1H-indol-3-yl)ethanone (Rathod et al., 2017) and ethyl 1-benzyl-2-methyl-5-((1-phenyl-1H-1,2,3-triazol-4-yl)methoxy)-1H-indole-3-carboxylate derivatives, some of which have shown selectivity and favorable *in vitro* activity against *Mtb*-DHFR (Sharma et al., 2019).









3.6. Miscellaneous indole-based compounds

Several indole-based compounds have also been reported for their activity against various strains of *Mtb* with diverse mechanisms of action. Ramesh et al. have designed, synthesized, and evaluated a series of indole chalcones against the H37Rv strain. Some compounds in the series, including (E)-1-(furan-3-yl)-3-(1H-indol-3-yl)prop-2-en-1-one (Khan et al., 2018), (E)-3-(1H-indol-3-yl)-1-(thiophene-2-yl)prop-2-en-1-one, and (E)-2-((1H-indol-2-yl)methylene)cyclopentane-1-one, have shown potential anti-tubercular activity at 50 mg/ml with MIC values of 210, 197, and 236 μM, respectively (Ramesh et al., 2020). Novel 1-substituted indole-3-carboxaldehyde thiosemicarbazones (Desai et al., 2016) have been synthesized and evaluated for their anti-mycobacterial activity. Compounds substituted with a propyl and 4-nitrobenzyl group have been found to have the highest potential and selective inhibition, with IC50 values of 0.9 and 1.9 μg/mL, respectively (Mashayekhi et al., 2021). The gut microbiota metabolite indole propionic acid [3-(1H-indol-3-yl)propanoic acid] (Chikhale et al., 2018) has been purified *in vivo* and evaluated in a mouse model of acute *Mtb* infection. This compound has been found to decrease the bacterial load in the spleen by sevenfold and is worthy of further exploration (Negatu et al., 2018). A series of novel hybrid hydrazides and hydrazide-hydrazones combining indole (Robertson et al., 2021) and pyridine nuclei have been designed, synthesized, and tested *in vitro* for their anti-mycobacterial activity. Some of the compounds have been found to have favorable activity against the INH-sensitive strain *Mtb* H37Rv, with promising MIC values (Velezheva et al., 2016). Triheterocycles containing indole-benzimidazole-based 1,2,3-triazole hybrid compounds (Shirude et al., 2013) have shown *in vitro* anti-tubercular activity against the strain, along with antioxidant activity (Ashok et al., 2018). A series of novel indole-based thiosemicarbazones (Chatterji et al., 2014) with potential anti-mycobacterial activity have also been reported (Mashayekhi et al., 2021). Indole diketo acids (Danne et al., 2018) have been identified to inhibit *Mtb* malate synthase (GlcB), part of the glyoxylate shunt, through high-throughput screening and structure-guided design (Libardo et al., 2018).

4. Structure-based drug design approach



Structure-based drug design approaches have been demonstrated to be successful in the field of non-transmissible and viral diseases but less effective in antibacterial drug development. Nevertheless, notable progress has been made in the past 20 years in understanding the pathogen molecular physiology of TB, beginning with the seminal publication of the *Mtb* genome in 1998 (Bruch et al., 2020). The availability of crystal structures of target proteins is essential in the structure-based drug design approach. The 3D crystal structure of a target protein is determined through various techniques, such as X-ray crystallography,

Table 7Indole-based compounds as co-crystallized ligands with *Mtb* proteins/enzymes.

Sr. No.	Proteins/enzymes with PDB IDs	Structure model of protein in complex with ligand	Co-crystallized ligand	Ref.
1.	<i>Mtb</i> tryptophan synthase (MtTrpAB) with inhibitor GSK2 ((1-[2-fluorobenzoyl]-N-methyl-2,3-dihydro-1H-indole-5-sulfonamide) PDB ID: 6U6C			(Michalska et al., 2020)
2.	Pantothenate synthetase in complex with 2-(5-methoxy-2-(5-methylpyridin-2-ylsulfonylcarbonyl)-1H-indol-1-yl) acetic acid PDB ID: 3IUE			(Hung et al., 2009)
3.	<i>Mtb</i> malate synthase in complex with 2-hydroxy-3-(1H-indol-3-yl) propanoic acid PDB ID: 5CAK			(Huang et al., 2016)
4.	<i>Mtb</i> ArgB in complex with 1H-indole-3-carbonitrile PDB ID: 7NN8			(Gupta et al., 2021)

(continued on next page)

Table 7 (continued)

Sr. No.	Proteins/enzymes with PDB IDs	Structure model of protein in complex with ligand	Co-crystallized ligand	Ref.
5.	<i>Mtb</i> cytochrome P450 CYP121 in complex with (3S,6S)-3-(4-hydroxybenzyl)-6-(1H-indol-3-ylmethyl) piperazine-2,5-dione. PDB ID: 4IQ9.			(Fonvielle et al., 2013)

cryo-electron microscopy, or nuclear magnetic resonance (Bajad et al., 2021b). Some crystal structures of *Mtb* proteins in complex with indole-based compounds have been deposited in the Protein Data Bank. The functional *Mtb* tryptophan synthase (MtTrpAB) is essential for the survival of *Mtb* and is a promising target for the discovery of novel anti-TB drugs. The crystal structure of MtTrpAB with the inhibitor GSK2 ((1-[2-fluorobenzoyl]-N-methyl-2,3-dihydro-1H-indole-5-sulfonamide) has been deposited in the Protein Data Bank under accession code 6U6C (Michalska et al., 2020). A fragment-growing and fragment linking strategy has been used to design pantothenate synthase inhibitors. The atomic coordinates and structure factors for enzyme-ligand complexes have been deposited in the Protein Data Bank under accession codes 3IMC, 3ISJ, 3IUB, 3IUE, 3IME, 3IVC, 3IVG, 3IVX, and 3IMG (Hung et al., 2009). Several novel binding chemotypes have been discovered through a fragment-based approach on GlcB from *Mtb*. The novel interaction observed between the indole-containing fragments and GlcB in the existing potent phenyl-diketo acid (PDKA) series of inhibitors has been found to be 100 times potent than that of the parent PDKA. All determined structures have been deposited in the Protein Data Bank (Huang et al., 2016). The fragment-based approach has been used to identify hits against enzymes involved in the pathways, ArgB, ArgC, ArgD, and ArgF. The crystal structure of ArgB in complex with 1H-indole-3-carbonitrile has also been deposited in the Protein Data Bank (Gupta et al., 2021). In *Mtb* CYP121, the indole-heme stacking interaction closely contacts the distal face of the heme group (Fonvielle et al., 2013).

5. Conclusion

Indole is one of the prime scaffolds used to synthesize analogs for various biological applications, including TB treatment. This scaffold is found in various bioactive molecules of natural and synthetic origin. Several mechanistic and computational studies of novel indole derivatives have been performed against mycobacteria to understand the modes of action of the compounds. Some novel synthesized indole bearing compounds have also been reported to have potent cell wall inhibition activity, including 2-hydroxy-4-(4-nitro-1,3-dioxoisindolin-2-yl) benzoic acid (IDDB40), H1L and N-(2-hydroxyethyl)-1-((6-methoxy-5-methylpyrimidin-4-yl) methyl)-6-methyl-1H pyrrolo[3,2-b] pyridine-3-carboxamide, with IC₅₀ values of 0.39 µg/ml, 1.6 µg/ml, and 0.032 µM, respectively. Designing indole-bearing cationic amphiphiles selectively targeting cell membrane permeabilization and depolarization has yielded potent anti-mycobacterial agents. Indole-based MmpL3 inhibitors such as indole-2-carboxamides, N-cyclooctyl-6-trifluoromethylindol-2-ylmethylamine, and N-(1-(adamantane-1-yl) ethyl)-4,6-dichloro-1H-indole-2-carboxamide have been reported to have favorable inhibitory activity. The success of the novel non-

covalent DprE1 inhibitor 1,4-azaindole, which is currently undergoing clinical trials for the treatment of *Mtb*, has been notable. Another DG167 indazole sulfonamide drug candidate with potent anti-tubercular activity may enter clinical trials, given the favorable results of early-stage development in preclinical studies. The role of the structure-based drug design approach expanded after the seminal publication of the *Mtb* genome in 1998. The availability of crystal structures of *Mtb* proteins complexed with indole-based compounds in the Protein Data Bank indicates the growth of the *in silico* drug design approach. Efforts to design and develop indole-based compounds may lead to the identification of potential anti-tubercular drugs effective against drug-resistant TB.

6. Future perspectives

Several indole-containing drug molecules are available on the market to treat various disease conditions. The development of anti-tubercular drugs with novel mechanistic properties can be accelerated by incorporating promising moieties such as indoles into molecules. The potential results of a diverse range of functionalized indole derivatives acting on multiple targets are highly encouraging for the discovery and development of indole-based anti-tubercular agents or drugs. The emergence of new synthesis methods and advances in computational drug design tools have provided tremendous opportunities for designing indole derivatives. Newer *in silico* approaches, such as fragment-based drug design and advances in virtual screening, will be instrumental in developing potent new compounds. In addition, the recent progress in structural biology methods has played a crucial role in target-based drug discovery (de Souza Neto et al., 2020). The potential molecules 1,4-azaindoles and DG167 indazole sulfonamide are currently under clinical development and may enter the market in the future to treat *Mtb*. Therefore, the discovery and development of indole-based therapeutics is an attractive potential approach for identifying potent and promising anti-tubercular drugs.

CRediT authorship contribution statement

Nilesh Gajanan Bajad: Conceptualization, Methodology, Writing – original draft. **Sudhir Kumar Singh:** Validation, Writing – review & editing. **Sushil Kumar Singh:** Supervision, Validation. **Tryambak Deo Singh:** Supervision, Investigation. **Meenakshi Singh:** Supervision, Conceptualization, Funding acquisition, Writing – review & editing.

Declaration of competing interest

The authors declare that they have no known competing financial

interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement

This work was supported by Institute of Eminence, Banaras Hindu University, Varanasi, India. SKS is grateful to the Institute of Eminence, Banaras Hindu University, Varanasi, India, for providing the Malaviya Postdoctoral Fellowship.

References

- Alsayed, S.S., Lun, S., Bailey, A.W., Suri, A., Huang, C.-C., Mocerino, M., et al., 2021. Design, synthesis and evaluation of novel indole-2-carboxamides for growth inhibition of *Mycobacterium tuberculosis* and paediatric brain tumour cells. *RSC Adv.* 11 (26), 15497–15511.
- Ashok, D., Gundu, S., Aamate, V.K., Devulapally, M.G., 2018. Conventional and microwave-assisted synthesis of new indole-tethered benzimidazole-based 1, 2, 3-triazoles and evaluation of their antimycobacterial, antioxidant and antimicrobial activities. *Mol. Divers.* 22 (4), 769–778.
- Baeyer, A., Knop, C., 1866. *Mittheilungen aus dem organischen Laboratorium der Gewerbe-Academie in Berlin. I. Untersuchungen über die Gruppe des Indigblaus.* Justus Liebigs Ann. Chem. 140 (1), 1–38.
- Bajad, N.G., Swetha, R., Gutti, G., Singh, M., Kumar, A., Singh, S.K., 2021a. A systematic review of carbohydrate-based bioactive molecules for Alzheimer's disease. *Future Med. Chem.* 13 (19), 1695–1711.
- Bajad, N.G., Rayala, S., Gutti, G., Sharma, A., Singh, M., Kumar, A., et al., 2021b. Systematic review on role of structure based drug design (SBDD) in the identification of anti-viral leads against SARS-Cov-2. *Curr. Pharmacol. Drug Discover.* 2, 100026.
- Bhaskar, K.A., Sureja, D.K., Dhameiliya, T.M., 2022. Synthetic account of indoles in search of potential anti-mycobacterial agents: a review and future insights. *J. Mol. Struct.* 1248, 131522.
- Biswal, S., Sahoo, U., Sethy, S., Kumar, H., Banerjee, M., 2012. Indole: the molecule of diverse biological activities. *Asian J. Pharmaceut. Clin. Res.* 5 (1), 1–6.
- Bolla, J.R., 2020. Targeting MmpL3 for anti-tuberculosis drug development. *Biochem. Soc. Trans.* 48 (4), 1463–1472.
- Borad, M.A., Bhoi, M.N., Rathwa, S.K., Vasava, M.S., Patel, H.D., Patel, C.N., et al., 2018. Microwave-assisted ZrSiO₂ catalysed synthesis, characterization and computational study of novel spiro [indole-thiazolidines] derivatives as anti-tubercular agents. *Interdiscipl. Sci. Comput. Life Sci.* 10 (2), 411–418.
- Bruch, E.M., Petrella, S., Bellinzoni, M., 2020. Structure-based drug design for tuberculosis: challenges still ahead. *Appl. Sci.* 10 (12), 4248.
- Bugaenko, D.I., Karchava, A.V., Yurovskaya, M.A., 2019. Synthesis of indoles: recent advances. *Russ. Chem. Rev.* 88 (2), 99.
- Bugg, T.D., Braddick, D., Dowson, C.G., Roper, D.I., 2011. Bacterial cell wall assembly: still an attractive antibacterial target. *Trends Biotechnol.* 29 (4), 167–173.
- Chatterji, M., Shandil, R., Manjunatha, M., Solapure, S., Ramachandran, V., Kumar, N., et al., 2014. 1, 4-Azaindole, a potential drug candidate for treatment of tuberculosis. *Antimicrobiol. Agents Chemother.* 58 (9), 5325–5331.
- Chen, H., Nyantakyi, S.A., Li, M., Gopal, P., Aziz, D.B., Yang, T., et al., 2018. The mycobacterial membrane: a novel target space for anti-tubercular drugs. *Front. Microbiol.* 9, 1627.
- Chetty, S., Ramesh, M., Singh-Pillay, A., Soliman, M.E., 2017. Recent advancements in the development of anti-tuberculosis drugs. *Bioorg. Med. Chem. Lett.* 27 (3), 370–386.
- Chikhale, R.V., Barmade, M.A., Murumkar, P.R., Yadav, M.R., 2018. Overview of the development of DprE1 inhibitors for combating the menace of tuberculosis. *J. Med. Chem.* 61 (19), 8563–8593.
- Danne, A.B., Choudhari, A.S., Chakraborty, S., Sarkar, D., Khedkar, V.M., Shingate, B.B., 2018. Triazole-diindolylmethane conjugates as new antitubercular agents: synthesis, bioevaluation, and molecular docking. *MedChemComm* 9 (7), 1114–1130.
- de Sa Alves, F.R., Barreiro, E.J., Manssour, F.R., 2009. From nature to drug discovery: the indole scaffold as a 'privileged structure'. *Mini Rev. Med. Chem.* 9 (7), 782–793.
- de Souza Neto, L.R., Moreira-Filho, J.T., Neves, B.J., Maidana, R.L.B.R., Guimarães, A.C.R., Furnham, N., et al., 2020. In silico strategies to support fragment-to-lead optimization in drug discovery. *Front. Chem.* 8, 93.
- Desai, N., Somani, H., Trivedi, A., Bhatt, K., Nawale, L., Khedkar, V.M., et al., 2016. Synthesis, biological evaluation and molecular docking study of some novel indole and pyridine based 1, 3, 4-oxadiazole derivatives as potential antitubercular agents. *Bioorg. Med. Chem. Lett.* 26 (7), 1776–1783.
- Dewangan, R.P., Singh, M., Ilic, S., Tam, B., Akabayov, B., 2021. Cell-penetrating peptide conjugates of indole-3-acetic acid-based DNA primase/Gyrase inhibitors as potent anti-tubercular agents against planktonic and biofilm culture of *Mycobacterium smegmatis*. *Chem. Biol. Drug Des.* 98 (5), 722–732.
- Dey, P., Kundu, A., Kumar, A., Gupta, M., Lee, B.M., Bhakta, T., et al., 2020. Analysis of alkaloids (indole alkaloids, isoquinoline alkaloids, tropane alkaloids). In: *Recent Advances in Natural Products Analysis*. Elsevier, pp. 505–567.
- Dighe, S.N., Collet, T.A., 2020. Recent advances in DNA gyrase-targeted antimicrobial agents. *Eur. J. Med. Chem.* 199, 112326.
- Ditze, Z., Lamers, M.H., Warner, D.F., 2017. DNA replication in *Mycobacterium tuberculosis*. *Microbiol. Spectr.* 5 (2), 5–2. 20.
- Fonville, M., Le Du, M.-H., Lequin, O., Lecoq, A., Jacquet, M., Thai, R., et al., 2013. Substrate and reaction specificity of *Mycobacterium tuberculosis* cytochrome P450 CYP121: insights from biochemical studies and crystal structures. *J. Biol. Chem.* 288 (24), 17347–17359.
- Franz, N.D., Belardinelli, J.M., Kaminski, M.A., Dunn, L.C., de Moura, V.C.N., Blaha, M.A., et al., 2017. Design, synthesis and evaluation of indole-2-carboxamides with pan antimycobacterial activity. *Bioorg. Med. Chem.* 25 (14), 3746–3755.
- Gassman, P.G., Van Bergen, T., Gilbert, D.P., Cue Jr., B.W., 1974. General method for the synthesis of indoles. *J. Am. Chem. Soc.* 96 (17), 5495–5508.
- Gupta, P., Thomas, S.E., Zaidan, S.A., Pasillas, M.A., Cory-Wright, J., Sebastián-Pérez, V., et al., 2021. A fragment-based approach to assess the ligandability of ArgB, ArgC, ArgD and ArgF in the L-arginine biosynthetic pathway of *Mycobacterium tuberculosis*. *Comput. Struct. Biotechnol. J.* 19, 3491–3506.
- Hamid, H.A., Ramli, A.N., Yusoff, M.M., 2017. Indole alkaloids from plants as potential leads for antidepressant drugs: a mini review. *Front. Pharmacol.* 8, 96.
- Hett, E.C., Rubin, E.J., 2008. Bacterial growth and cell division: a mycobacterial perspective. *Microbiol. Mol. Biol. Rev.* 72 (1), 126–156.
- Huang, H.-L., Krieger, I.V., Parai, M.K., Gawandi, V.B., Sacchetti, J.C., 2016. *Mycobacterium tuberculosis* malate synthase structures with fragments reveal a portal for substrate/product exchange. *J. Biol. Chem.* 291 (53), 27421–27432.
- Humphrey, G.R., Kuethe, J.T., 2006. Practical methodologies for the synthesis of indoles. *Chem. Rev.* 106 (7), 2875–2911.
- Hung, A.W., Silvestre, H.L., Wen, S., Ciulli, A., Blundell, T.L., Abell, C., 2009. Application of fragment growing and fragment linking to the discovery of inhibitors of *Mycobacterium tuberculosis* pantothenate synthetase. *Angew. Chem. Int. Ed.* 48 (45), 8452–8456.
- Inoyama, D., Awasthi, D., Capodagli, G.C., Tsoetsi, K., Sukheja, P., Zimmerman, M., et al., 2020. A preclinical candidate targeting *Mycobacterium tuberculosis* KasA. *Cell. Chem. Biol.* 27 (5), 560–570 e10.
- Islam, M.I., Seo, H., Kim, S., Sadu, V.S., Lee, K.-I., Song, H.-Y., 2021. Antimicrobial activity of IDD-B40 against drug-resistant *Mycobacterium tuberculosis*. *Sci. Rep.* 11 (1), 1–9.
- Jankute, M., Cox, J.A., Harrison, J., Besra, G.S., 2015. Assembly of the mycobacterial cell wall. *Annu. Rev. Microbiol.* 69, 405–423.
- Jeffrey North, E., Jackson, M., E Lee, R., 2014. New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics. *Curr. Pharmaceut. Des.* 20 (27), 4357–4378.
- Kashyap, A., Singh, P.K., Silakari, O., 2018. In silico designing of domain B selective gyrase inhibitors for effective treatment of resistant tuberculosis. *Tuberculosis* 112, 83–88.
- Khan, A., Jasinski, J.P., Smolenski, V.A., Hotchkiss, E.P., Kelley, P.T., Shalit, Z.A., et al., 2018. Enhancement in anti-tubercular activity of indole based thiosemicarbazones on complexation with copper (I) and silver (I) halides: structure elucidation, evaluation and molecular modelling. *Bioorg. Chem.* 80, 303–318.
- Khanapur, M., Alvala, M., Prabhakar, M., Kumar, K.S., Edwin, R., Saranya, P.S., et al., 2017. *Mycobacterium tuberculosis* chorismate mutase: a potential target for TB. *Bioorg. Med. Chem.* 25 (6), 1725–1736.
- Khawbong, J.L., Nath, D., Chakraborty, S., 2021. Drug resistant tuberculosis: a review. *Comp. Immunol. Microbiol. Infect. Dis.* 74, 101574.
- Kleinhaus, K., Brandl, C., Brandl, L., Ebert, G., Jirschele, R., Maala, N., Neumeyer, P., Schneider, G., Schuh, L., Weyker, E., Olson, A., 2010 Apr. Inhibiting Dihydrofolate Reductase as a Treatment for Tuberculosis. *FASEB J.* 24, 1b118.
- Kochanowska-Karamyan, A.J., Hamann, M.T., 2010. Marine indole alkaloids: potential new drug leads for the control of depression and anxiety. *Chem. Rev.* 110 (8), 4489–4497.
- Kontsevaya, I., Lange, C., Comella-del-Barrio, P., Coarfa, C., DiNardo, A.R., Gillespie, S.H., et al., 2021. Perspectives for systems biology in the management of tuberculosis. *Eur. Respir. Rev.* 30 (160).
- Kumar, K.S., Rambabu, D., Sandra, S., Kapavarapu, R., Krishna, G.R., Rao, M.B., et al., 2012. AlCl₃ induced (hetero) arylation of 2, 3-dichloroquinoline: a one-pot synthesis of mono/disubstituted quinoxalines as potential antitubercular agents. *Bioorg. Med. Chem.* 20 (5), 1711–1722.
- Kumar, P., Capodagli, G.C., Awasthi, D., Shrestha, R., Maharaja, K., Sukheja, P., et al., 2018. Synergistic lethality of a binary inhibitor of *Mycobacterium tuberculosis* KasA. *mBio* 9 (6), e021101–e02117.
- Kumar, A., Karkara, B.B., Panda, G., 2021. Novel candidates in the clinical development pipeline for TB drug development and their synthetic approaches. *Chem. Biol. Drug Des.* 98 (5), 787–827.
- Kumari, A., Singh, R.K., 2019. Medicinal chemistry of indole derivatives: current to future therapeutic perspectives. *Bioorg. Chem.* 89, 103021.
- Kuo, M.R., Morbidoni, H.R., Alland, D., Sneddon, S.F., Gourlie, B.B., Staveski, M.M., et al., 2003. Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and structural data. *J. Biol. Chem.* 278 (23), 20851–20859.
- Li, M., Nyantakyi, S.A., Gopal, P., Aziz, D.B., Dick, T., Go, M.-L., 2017. Indolylalkyltriphenylphosphonium analogues are membrane-depolarizing mycobactericidal agents. *ACS Med. Chem. Lett.* 8 (11), 1165–1170.
- Libardo, M.D.J., Boshoff, H.I., Barry III, C.E., 2018. The present state of the tuberculosis drug development pipeline. *Curr. Opin. Pharmacol.* 42, 81–94.
- Lun, S., Guo, H., Onajole, O.K., Pieroni, M., Gunosewoyo, H., Chen, G., et al., 2013. Indoleamides are active against drug-resistant *Mycobacterium tuberculosis*. *Nat. Commun.* 4 (1), 1–8.
- Mashayekhi, V., Haj Mohammad Ebrahim Tehrani, K., Azerang, P., Sardari, S., Kobarfard, F., 2021. Synthesis, antimycobacterial and anticancer activity of novel indole-based thiosemicarbazones. *Arch. Pharm. Res. (Seoul)* 44 (8), 1–13.
- Matviuk, T., Rodriguez, F., Saffon, N., Mallet-Ladeira, S., Gorichko, M., Ribeiro, A.L.J.L., et al., 2013. Design, chemical synthesis of 3-(9H-fluoren-9-yl) pyrrolidine-2, 5-dione

- derivatives and biological activity against enoyl-ACP reductase (InhA) and *Mycobacterium tuberculosis*. *Eur. J. Med. Chem.* 70, 37–48.
- Michalska, K., Chang, C., Maltseva, N.I., Jedrzejczak, R., Robertson, G.T., Gusovsky, F., et al., 2020. Allosteric inhibitors of *Mycobacterium tuberculosis* tryptophan synthase. *Protein Sci.* 29 (3), 779–788.
- Mitchison, D.A., Davies, G.R., 2008. Assessment of the efficacy of new anti-tuberculosis drugs. *Open Infect. Dis. J.* 2, 59.
- Nakhi, A., Prasad, B., Reddy, U., Rao, R.M., Sandra, S., Kapavarapu, R., et al., 2011. A new route to indoles via in situ desilylation–Sonogashira strategy: identification of novel small molecules as potential anti-tuberculosis agents. *MedChemComm* 2 (10), 1006–1010.
- Negatu, D.A., Liu, J.J., Zimmerman, M., Kaya, F., Dartois, V., Aldrich, C.C., et al., 2018. Whole-cell screen of fragment library identifies gut microbiota metabolite indole propionic acid as antitubercular. *Antimicrobiol. Agents Chemother.* 62 (3).
- Neto, J.S.S., Zeni, G., 2020. Recent advances in the synthesis of indoles from alkynes and nitrogen sources. *Org. Chem. Front.* 7 (1), 155–210.
- Prasad, B., Adepur, R., Sandra, S., Rambabu, D., Krishna, G.R., Reddy, C.M., et al., 2012. AlCl₃ mediated unexpected migration of sulfonyl groups: regioselective synthesis of 7-sulfonyl indoles of potential pharmacological interest. *Chem. Commun.* 48 (84), 10434–10436.
- Ramesh, D., Joji, A., Vijayakumar, B.G., Sethumadhavan, A., Mani, M., Kannan, T., 2020. Indole chalcones: design, synthesis, in vitro and in silico evaluation against *Mycobacterium tuberculosis*. *Eur. J. Med. Chem.* 198, 112358.
- Rathod, A.S., Godipurge, S.S., Biradar, J.S., 2017. Synthesis of indole, coumarinyl and pyridinyl derivatives of isoniazid as potent antitubercular and antimicrobial agents and their molecular docking studies. *Int. J. Pharm. Pharmaceut. Sci.* 9, 233–240.
- Rayasam, G.V., 2014. MmpL3 a potential new target for development of novel anti-tuberculosis drugs. *Expert Opin. Ther. Targets* 18 (3), 247–256.
- Reddy, G.S., Snehalatha, A.V., Edwin, R.K., Hossain, K.A., Giliyaru, V.B., Hariharapura, R.C., et al., 2019. Synthesis of 3-indolylmethyl substituted (pyrazolo/benzo) triazinone derivatives under Pd/Cu-catalysis: identification of potent inhibitors of chorismate mutase (CM). *Bioorg. Chem.* 91, 103155.
- Reddy, G.S., Hossain, K.A., Kumar, J.S., Thirupataiah, B., Edwin, R.K., Giliyaru, V.B., et al., 2020. Novel isatin–indole derivatives as potential inhibitors of chorismate mutase (CM): their synthesis along with unexpected formation of 2-indolylmethylamino benzoate ester under Pd–Cu catalysis. *RSC Adv.* 10 (1), 289–297.
- Reiche, M.A., Warner, D.F., Mizrahi, V., 2017. Targeting DNA replication and repair for the development of novel therapeutics against tuberculosis. *Front. Mol. Biosci.* 4, 75.
- Rivers, E.C., Mancera, R.L., 2008. New anti-tuberculosis drugs in clinical trials with novel mechanisms of action. *Drug Discov. Today* 13 (23–24), 1090–1098.
- Robertson, G.T., Ramey, M.E., Massoudi, L.M., Carter, C.L., Zimmerman, M., Kaya, F., et al., 2021. Comparative analysis of pharmacodynamics in the C3HeB/FeJ mouse tuberculosis model for DprE1 inhibitors TBA-7371, PBTZ169, and OPC-167832. *Antimicrobiol. Agents Chemother.* 65 (11) e00583-21.
- Rosales, P.F., Bordin, G.S., Gower, A.E., Moura, S., 2020. Indole alkaloids: 2012 until now, highlighting the new chemical structures and biological activities. *Fitoterapia* 143, 104558.
- Rožman, K., Sosić, I., Fernandez, R., Young, R.J., Mendoza, A., Gobec, S., et al., 2017. A new 'golden age' for the antitubercular target InhA. *Drug Discov. Today* 22 (3), 492–502.
- Sanna, G., Madeddu, S., Giliberti, G., Piras, S., Struga, M., Wrzosek, M., et al., 2018. Synthesis and biological evaluation of novel indole-derived thioureas. *Molecules* 23 (10), 2554.
- Sharma, K., Tanwar, O., Sharma, S., Ali, S., Alam, M., Zaman, M., et al., 2018. Structural comparison of Mtb-DHFR and h-DHFR for design, synthesis and evaluation of selective non-pteridine analogues as antitubercular agents. *Bioorg. Chem.* 80, 319–333.
- Sharma, K., Tanwar, O., Deora, G.S., Ali, S., Alam, M., Zaman, M., et al., 2019. Expansion of a novel lead targeting M. tuberculosis DHFR as antitubercular agents. *Bioorg. Med. Chem.* 27 (7), 1421–1429.
- Shirude, P.S., Shandil, R., Sadler, C., Naik, M., Hosagrahara, V., Hameed, S., et al., 2013. Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill *Mycobacterium tuberculosis* and are efficacious in vivo. *J. Med. Chem.* 56 (23), 9701–9708.
- Singh, M., Ilic, S., Tam, B., Ben-Ishay, Y., Sherf, D., Pappo, D., et al., 2020. Dual-acting small-molecule inhibitors targeting mycobacterial DNA replication. *Chem.–Eur. J.* 26 (47), 10849–10860.
- Tan, Y.J., Li, M., Gunawan, G.A., Nyantakyi, S.A., Dick, T., Go, M.-L., et al., 2020. Amide–amine replacement in indole-2-carboxamides yields potent mycobactericidal agents with improved water solubility. *ACS Med. Chem. Lett.* 12 (5), 704–712.
- Velezheva, V., Brennan, P., Ivanov, P., Kornienko, A., Lyubimov, S., Kazarian, K., et al., 2016. Synthesis and antituberculosis activity of indole–pyridine derived hydrazides, hydrazide–hydrazones, and thiosemicarbazones. *Bioorg. Med. Chem. Lett.* 26 (3), 978–985.
- Yadav, N., Khanam, T., Shukla, A., Rai, N., Hajela, K., Ramachandran, R., 2015. Tricyclic dihydrobenzoxazepine and tetracyclic indole derivatives can specifically target bacterial DNA ligases and can distinguish them from human DNA ligase I. *Org. Biomol. Chem.* 13 (19), 5475–5487.
- Yang, T., Moreira, W., Nyantakyi, S.A., Chen, H., Aziz, D.B., Go, M.-L., et al., 2017. Amphiphilic indole derivatives as antimycobacterial agents: structure–activity relationships and membrane targeting properties. *J. Med. Chem.* 60 (7), 2745–2763.
- Yang, X., Hu, T., Yang, X., Xu, W., Yang, H., Guddat, L.W., et al., 2020. Structural basis for the inhibition of mycobacterial MmpL3 by NITD-349 and SPIRO. *J. Mol. Biol.* 432 (16), 4426–4434.